Vertex Pharmaceuticals has three key ways to deliver strong growth, including its cystic fibrosis franchise, new non-CF products, and a promising pipeline. The company’s late-stage track record is solid, but there is a risk of pipeline setbacks. Vertex’s revenue is driven by Kaftrio/Trikafta, which accounted for 86% of total revenue in Q2 2025. The company also has promising new therapies like Alyftrek and Journavx. Vertex’s pipeline includes zimislecel, povetacicept, and inaxaplin targeting various diseases affecting millions of patients. Despite risks, Vertex Pharmaceuticals is positioned for significant growth in the future.

Read more at Yahoo Finance: My Top Growth Stock to Buy in November